Semaglutide 2.4mg for Low Responders After Bariatric Surgery

NCT06287307 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide (2.4mg) can help people who have had bariatric surgery but did not lose enough weight, by measuring changes in weight over 15 months.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 152 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2024-05 · est. completion 2026-09

What this study is testing ClinicalTrials.gov NCT06287307 ↗

Description as written by the study sponsor.

In 20 - 30% of the patients, the low responders, sufficient weight loss is not achieved after bariatric surgery. Secondary and/or tertiary bariatric procedures can lead to successful weight loss and resolution of comorbid conditions though, morbidity and mortality rates of these procedures are high. Therefore, additional pharmacotherapy has been suggested. Semaglutide is one of the medications that might improve outcome in the post-bariatric population. Semaglutide is a Glucagon-like peptide-1 (GLP-1) receptor analogue developed to treat type 2 diabetes. It causes glucose-dependent insulin secretion, promotes satiety and inhibits glucagon secretion. In obese (non-bariatric) patients, semaglutide has shown to improve glycemic control, decrease blood pressure, lower cardiovascular risk, and decrease body weight.

Treatments tested

Placebo Other

The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.
Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] also known as Wegovy, Semaglutide Drug

The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.

Main thing measured	Weight change from start study at 3 months post operative until 15 months later
Sponsor	Zuyderland Medisch Centrum
Conditions studied	Obesity, Obesity, Morbid, Weight Gain
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06287307 ↗